First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park

Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers. Over the last five years, it has been used for patients with relapsed diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Recently, CAR T therapy was approved by the FDA to treat patients with relapsed/refractory chronic lymphocytic leukemia (CLL). With currently available CAR T therapy products, long-term cancer control can be observed in around 40% of patients. There is a need to develop better forms of CAR T therapies to maximize their potential.

"Armored" CART-cells are a new generation of CAR T products that are being evaluated in clinical trials. Roswell Park Comprehensive Cancer Center is conducting a first-in-human ). This enhanced form of immunotherapy was developed by Roswell Park scientists in collaboration with scientists at Memorial Sloan Kettering. 

The T cells used in this trial will be manufactured at Roswell Park's expanded state-of-the-art for the first time. "We will have the infrastructure, the process, the support structure to not only manufacture cells for therapy but also to be able to support a clinical trial and have the resources in place to be able to infuse these therapies into a patient,” says Senior Vice President of Industry Partnerships and Technical Director of GMP Facility at Roswell Park.

Related Presenters

Yeong “Christopher” Choi PhD, MBA.


Francisco Hernandez-Ilizaliturri, MD.

Hematologic Oncology